Symmetry Investments’s Maravai LifeSciences MRVI Stock Holding History

Symmetry Investments’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.02M	Buy	359,561 +100,528	+39%	+$341K	0.11%	92
2025 Q4	$842K	Sell	259,033 -25,967	-9%	-$87.4K	0.07%	126
2025 Q3	$818K	Buy	285,000 +54,000	+23%	+$138K	0.04%	120
2025 Q2	$557K	Buy	231,000 +31,000	+16%	+$65.2K	0.04%	115
2025 Q1	$442K	Buy	200,000 +135,000	+208%	+$533K	0.03%	130
2024 Q4	$354K	Buy	65,000 +30,000	+86%	+$193K	0.02%	151
2024 Q3	$291K	Sell	35,000 -80,000	-70%	-$692K	0.04%	112
2024 Q2	$823K	Buy	+115,000	New	+$993K	0.09%	117

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Symmetry Investments's MRVI Position: Q1 2026 in Review

Symmetry Investments increased its Maravai LifeSciences (MRVI) stake by 39% in Q1 2026, buying an estimated $341K and bringing the position to 359,561 shares worth $1.02M. The position accounts for 0.11% of the portfolio, ranked #92.

Symmetry Investments first reported a position in MRVI in Q2 2024 and has held it in 8 quarters since. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

Symmetry Investments held 359,561 shares of Maravai LifeSciences worth $1.02M as of Q1 2026.
Symmetry Investments bought 100,528 Maravai LifeSciences shares in Q1 2026, an estimated $341K.
Maravai LifeSciences made up 0.11% of Symmetry Investments's portfolio in Q1 2026, its #92 holding.
Symmetry Investments first reported a position in Maravai LifeSciences in Q2 2024 and has held it in 8 quarters since.
158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Symmetry Investments's 13F filing for Q1 2026, filed 15 May 2026.